Clinically, IDH1/2-mutant gliomas were associated with lower headache incidence (32.2% versus 50.4% in IDH1/2-wild-type gliomas; P < 0.0001) but higher epilepsy prevalence (36.0% versus 16.9%; P < 0.001). Here, IDH1 is linked to central nervous system cancer.